MC0518 clinical trials

Efficacy of cell therapy with allo-MSCs in patients with gvhd resistant to ruxolitinib second line therapy: a Phase IIB Clinical Trial - MSC-GRR2 Study

This study is testing a new cell therapy (MC0518) for people with a serious problem called GVHD, which hasn't responded to usual treatments like ruxolitinib and steroids. We want to see if this new treatment helps improve their condition within 28 days.